BLINATUMOMAB + Venetoclax for neoplasm, residual

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Dec 2021: Trial started, NCT05182385
  2. 10 Jan 2022: Trial registered, NCT05182385

The trials

NCT05182385: Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

State
Under way
Phase
Phase 1 and Phase 2
People
30 taking part
Started
15 Dec 2021
Primary completion
30 Apr 2026
Arms
hematological relapse, molecular relapse
Results
None posted
  1. 15 Dec 2021: Trial started
  2. 10 Jan 2022: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.